ID: ALA2063141

Max Phase: Preclinical

Molecular Formula: C18H34O

Molecular Weight: 266.47

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H](O)CCC[C@]12C

Standard InChI:  InChI=1S/C18H34O/c1-13(2)7-5-8-14(3)15-10-11-16-17(19)9-6-12-18(15,16)4/h13-17,19H,5-12H2,1-4H3/t14-,15-,16+,17+,18-/m1/s1

Standard InChI Key:  KJWMQESDDWGHHO-DFBDCSAJSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 266.47

Molecular Weight (Monoisotopic): 266.2610

AlogP: 5.03

#Rotatable Bonds: 5

Polar Surface Area: 20.23

Molecular Species: NEUTRAL

HBA: 1

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 1

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa:

CX LogP: 5.30

CX LogD: 5.30

Aromatic Rings: 0

Heavy Atoms: 19

QED Weighted: 0.74

Np Likeness Score: 2.43

References

1. DeBerardinis AM, Banerjee U, Miller M, Lemieux S, Hadden MK..  (2012)  Probing the structural requirements for vitamin D3 inhibition of the hedgehog signaling pathway.,  22  (14): [PMID:22687748] [10.1016/j.bmcl.2012.05.037]

2. DeBerardinis AM, Banerjee U, Hadden MK..  (2013)  Identification of vitamin d3-based hedgehog pathway inhibitors that incorporate an aromatic a-ring isostere.,  4  (7): [PMID:24900716] [10.1021/ml400014t]

3. Deberardinis AM, Madden DJ, Banerjee U, Sail V, Raccuia DS, De Carlo D, Lemieux SM, Meares A, Hadden MK..  (2014)  Structure-activity relationships for vitamin D3-based aromatic a-ring analogues as hedgehog pathway inhibitors.,  57  (9): [PMID:24730984] [10.1021/jm401812d]

4. DeBerardinis AM, Raccuia DS, Thompson EN, Maschinot CA, Kyle Hadden M..  (2015)  Vitamin D3 analogues that contain modified A- and seco-B-rings as hedgehog pathway inhibitors.,  93  [PMID:25676864] [10.1016/j.ejmech.2015.01.049]

Source

Source(1):

• Scientific Literature